[
  {
    "ts": null,
    "headline": "Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=2573646c67134dbdaeb7d8481bffd74cd402f21c10395b958d4861e889cc0adf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770386404,
      "headline": "Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know",
      "id": 138375515,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=2573646c67134dbdaeb7d8481bffd74cd402f21c10395b958d4861e889cc0adf"
    }
  },
  {
    "ts": null,
    "headline": "Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation",
    "summary": "Abbott (NYSE: ABT) today announced new clinical data from two late-breaking presentations at AF Symposium in Boston (February 5-7, 2026) that demonstrate the strong safety and efficacy of the company's minimally invasive therapies to treat people with atrial fibrillation (AFib). The results include 12-month findings that reinforce the long-term safety and performance of Abbott's Volt™ Pulsed Field Ablation (PFA) System, which were simultaneously published in JACC: Clinical Electrophysiology. Pos",
    "url": "https://finnhub.io/api/news?id=680d64ecb280550eb3c4dee60bce8b6c1018ed13affb28541a8a955ac1dc874d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770382800,
      "headline": "Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation",
      "id": 138374451,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (NYSE: ABT) today announced new clinical data from two late-breaking presentations at AF Symposium in Boston (February 5-7, 2026) that demonstrate the strong safety and efficacy of the company's minimally invasive therapies to treat people with atrial fibrillation (AFib). The results include 12-month findings that reinforce the long-term safety and performance of Abbott's Volt™ Pulsed Field Ablation (PFA) System, which were simultaneously published in JACC: Clinical Electrophysiology. Pos",
      "url": "https://finnhub.io/api/news?id=680d64ecb280550eb3c4dee60bce8b6c1018ed13affb28541a8a955ac1dc874d"
    }
  }
]